🔎 Trials Near Me

Nyumbani › Limfoma ya Hodgkin › Texas

Majaribio ya kliniki ya Limfoma ya Hodgkin katika jimbo la Texas

Masomo 15 ya Limfoma ya Hodgkin yanatafuta washiriki katika vituo vya jimbo la Texas.

Miji katika jimbo la Texas

Maandishi rasmi ya utafiti (Kiingereza)

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

  • Houston Methodist Hospital, Houston
  • Texas Children's Hospital, Houston
InaajiriHatua 1
Umri 12 hadi 75 · Jinsia zote · Imesasishwa 2 Okt 2026 · NCT06176690

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

  • Houston Methodist Hospital, Houston
  • Texas Children's Hospital, Houston
InaajiriHatua 1
Umri 12 hadi 75 · Jinsia zote · Imesasishwa 2 Okt 2026 · NCT02917083

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Texas Children's Hospital, Houston
InaajiriUtafiti wa uchunguzi
Umri 0 hadi 38 · Jinsia zote · Imesasishwa 1 Okt 2026 · NCT06131801

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

  • M D Anderson Cancer Center, Houston
InaajiriHatua 2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 18 Sep 2026 · NCT05615636

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

  • Sarah Cannon Research Institute at St. David's South Austin, Austin
InaajiriHatua 1
Umri 18 hadi 100 · Jinsia zote · Imesasishwa 15 Sep 2026 · NCT05798897

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

  • Research Site, Houston
InaajiriHatua 1/2
Umri 12 na zaidi · Jinsia zote · Imesasishwa 14 Sep 2026 · NCT06137144

Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

  • The University of Texas M. D. Anderson Cancer Center, Houston
InaajiriHatua 1
Umri 18 hadi 75 · Jinsia zote · Imesasishwa 8 Sep 2026 · NCT07444632

Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

  • UT MD Anderson, Houston
InaajiriHatua 2
Umri 2 hadi 21 · Jinsia zote · Imesasishwa 31 Ago 2026 · NCT07551583

Personalized NK Cell Therapy in CBT

  • M D Anderson Cancer Center, Houston
InaajiriHatua 2
Umri 15 hadi 80 · Jinsia zote · Imesasishwa 30 Jul 2026 · NCT02727803

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Medical City Dallas, Dallas
  • Children's Medical Center Dallas, Dallas
  • Zachary & Elizabeth Fisher Bone Marrow Transplant Program (Brooke Army Medical Center), Fort Sam Houston
  • na zaidi ya 5
InaajiriUtafiti wa uchunguzi
Umri wote · Jinsia zote · Imesasishwa 6 Jul 2026 · NCT01351545

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

  • Harris Health System - Ben Taub General Hospital/Smith Clinic, Houston
  • Houston Methodist Hospital, Houston
  • Texas Children's Hospital, Houston
  • na zaidi ya 1
InaajiriHatua 1
Umri wote · Jinsia zote · Imesasishwa 25 Jun 2026 · NCT04664179

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

  • MD Anderson Cancer Center, Houston
InaajiriHatua 2Wajitolea wenye afya wanakaribishwa
Umri 1 na zaidi · Jinsia zote · Imesasishwa 18 Mei 2026 · NCT05355051

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

  • Harris Health System (includes ben Taub General Hospital and Smith), Houston
  • Houston Methodist Hospital, Houston
  • Texas Children's Hospital, Houston
InaajiriHatua 1
Umri wote · Jinsia zote · Imesasishwa 2 Mac 2026 · NCT01555892

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • University of Texas, Southwestern, Dallas
  • Cook Children's Hospital, Fort Worth
  • Texas Children's Hospital/Baylor College of Medicine, Houston
InaajiriHatua 1
Umri 1 hadi 21 · Jinsia zote · Imesasishwa 6 Des 2024 · NCT05476770

Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.